MDT

86.08

+0.56%↑

A

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

MDT

86.08

+0.56%↑

A

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

MDT

86.08

+0.56%↑

A

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

MDT

86.08

+0.56%↑

A

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

MDT

86.08

+0.56%↑

A

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

Search

Harmony Biosciences Holdings Inc

Chiusa

SettoreSettore sanitario

29.98 1.94

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

29.83

Massimo

30.11

Metriche Chiave

By Trading Economics

Entrata

-28M

22M

Vendite

4.3M

244M

P/E

Media del settore

10.72

63.808

Margine di Profitto

9.224

Dipendenti

293

EBITDA

-22M

52M

Raccomandazioni

By TipRanks

Raccomandazioni

Acquista

Previsioni per 12 mesi

+37.55% upside

Dividendi

By Dow Jones

Utili prossimi

5 mag 2026

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

133M

1.7B

Apertura precedente

28.04

Chiusura precedente

29.98

Notizie sul Sentiment di mercato

By Acuity

100%

0%

335 / 348 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Weak Bullish Evidence

Harmony Biosciences Holdings Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

17 apr 2026, 20:26 UTC

Acquisizioni, Fusioni, Takeovers

UCB to Buy Neurona Therapeutics for Up to $1.15 Billion

17 apr 2026, 18:15 UTC

Principali Notizie su Eventi

Fed's Waller: Prolonged Iran Conflict Could Block Path to Rate Cuts

17 apr 2026, 16:49 UTC

Principali Notizie su Eventi

Week Ahead for FX, Bonds: U.S. Retail Sales, PMI -2-

18 apr 2026, 01:00 UTC

Principali Notizie su Eventi

As Economic Pressures Mount, Will Iran or the U.S. Blink First? -- WSJ

17 apr 2026, 22:58 UTC

Utili

Grupo Aeroportuario Del Pacifico: Announces Filing of 2025 Annual Report and Form 20-F

17 apr 2026, 21:32 UTC

Discorsi di Mercato

Cerebras IPO Adds to Big Year For AI Firms Going Public -- Market Talk

17 apr 2026, 21:22 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

17 apr 2026, 21:22 UTC

Discorsi di Mercato

Moody's Downgrades Belgium to A1 -- Market Talk

17 apr 2026, 20:52 UTC

Utili

Schwab Investors Get Spooked by JPMorgan's AI Strategy. The Big Worry Is Cash Sweeps. -- Barrons.com

17 apr 2026, 20:50 UTC

Discorsi di Mercato
Utili
Acquisizioni, Fusioni, Takeovers

Tech, Media & Telecom Roundup: Market Talk

17 apr 2026, 20:50 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

17 apr 2026, 20:29 UTC

Utili

These Stocks Are Today's Movers: Royal Caribbean, Dow Inc., Netflix, Intel, Albemarle, Autoliv, Alcoa, and More -- Barrons.com

17 apr 2026, 20:11 UTC

Acquisizioni, Fusioni, Takeovers

UCB to Buy Neurona Therapeutics for Up to $1.15B

17 apr 2026, 19:34 UTC

Discorsi di Mercato
Utili
Acquisizioni, Fusioni, Takeovers

Global Equities Roundup: Market Talk

17 apr 2026, 19:34 UTC

Discorsi di Mercato
Utili
Acquisizioni, Fusioni, Takeovers

Analysts See Netflix's Deal Commentary as Notable -- Market Talk

17 apr 2026, 19:31 UTC

Discorsi di Mercato
Principali Notizie su Eventi

Oil Futures Fall on Reopening of Strait of Hormuz -- Market Talk

17 apr 2026, 19:26 UTC

Discorsi di Mercato

U.S. Natural Gas Futures Edge Up -- Market Talk

17 apr 2026, 19:21 UTC

Discorsi di Mercato

Albemarle's Outperformance Belies Longer-Term Risks -- Market Talk

17 apr 2026, 19:15 UTC

Discorsi di Mercato

Danaher Seen Rebounding in 2H After Tools-Sector Weakness -- Market Talk

17 apr 2026, 19:07 UTC

Discorsi di Mercato

Danaher Faces Tough Comparative but Long‑Term Story Intact -- Market Talk

17 apr 2026, 18:57 UTC

Principali Notizie su Eventi

U.S. Stocks Surge on Hope Iran War Nearing End. Foreign Leaders Have a More Sober View. -- Barrons.com

17 apr 2026, 18:53 UTC

Acquisizioni, Fusioni, Takeovers

UCB Expects 2026 Adjusted Ebitda Growth in High Single-Digit to Mid-Teens Percentage Range at Constant Exchange Rates

17 apr 2026, 18:53 UTC

Acquisizioni, Fusioni, Takeovers

UCB 2026 Rev Guidance Unchanged

17 apr 2026, 18:52 UTC

Acquisizioni, Fusioni, Takeovers

UCB: Neurona Deal to Include $650M Upfront and Up to $500M in Potential Future Milestones

17 apr 2026, 18:52 UTC

Acquisizioni, Fusioni, Takeovers

UCB to Acquire Neurona Therapeutics for Up to $1.15B Including Potential Milestones

17 apr 2026, 18:14 UTC

Discorsi di Mercato
Principali Notizie su Eventi

Precious Metals Close Higher as Stronger Demand Eyed -- Market Talk

17 apr 2026, 18:00 UTC

Principali Notizie su Eventi

Fed's Waller: Quick Resolution in Middle East Could Allow Cuts Later This Year

17 apr 2026, 18:00 UTC

Principali Notizie su Eventi

Fed's Waller: Job Losses May Not Signal Recession Amid Demographic Changes

17 apr 2026, 17:31 UTC

Discorsi di Mercato
Principali Notizie su Eventi

U.S. Oil Rig Count Down By 1 at 410 -- Market Talk

17 apr 2026, 17:26 UTC

Discorsi di Mercato
Utili

Netflix's Ability to Grow Engagement Seen as Up in the Air -- Market Talk

Confronto tra pari

Modifica del prezzo

Harmony Biosciences Holdings Inc Previsione

Obiettivo di Prezzo

By TipRanks

37.55% in crescita

Previsioni per 12 mesi

Media 41.25 USD  37.55%

Alto 62 USD

Basso 25 USD

Basato su 8 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Harmony Biosciences Holdings Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

8 ratings

4

Acquista

3

Mantieni

1

Vendi

Punteggio Tecnico

By Trading Central

29.8 / N/ASupporto e resistenza

A breve termine

Weak Bullish Evidence

A termine intermedio

Weak Bullish Evidence

A lungo termine

Very Strong Bearish Evidence

Sentiment

By Acuity

335 / 348 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Prove ribassiste molto forti

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sotto la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.
help-icon Live chat